국가: 아일랜드
언어: 영어
출처: HPRA (Health Products Regulatory Authority)
Furosemide
Pinewood Laboratories Ltd
C03CA01
Furosemide
Tablet
furosemide
Not marketed
2023-10-20
Health Products Regulatory Authority 20 October 2023 CRN00CQ58 Page 1 of 7 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Furosemide Pinewood 20 mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Furosemide Pinewood 20 mg Tablets each contain 20 mg Furosemide. Excipient with known effect Each tablet contains 52.5 mg lactose monohydrate. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Tablet. White to off white, round tablets, (6.00mm±0.2mm) marked F 20 on one side & plain on other side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Furosemide Pinewood 20 mg Tablets is used for the management of fluid retention and for the management of mild to moderate hypertension, either alone or as an adjunct. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _General_ The dose used must be the lowest that is sufficient to achieve the desired effect. Furosemide Pinewood 20 mg Tablets has an exceptionally wide therapeutic range, the effect being proportional to the dosage. Furosemide Pinewood 20 mg Tablets is best given as a single dose either daily or on alternate days. The usual initial daily dose is 40 mg. This may require adjustment until the effective dose is achieved as a maintenance dose. In mild cases, 20 mg daily or 40 mg on alternate days may be sufficient, whereas in cases of resistant oedema, daily doses of 80 mg and above may be used as one or two doses daily, or intermittently. Severe cases may require gradual titration of the furosemide dosage up to 600 mg daily. The recommended maximum daily dose of furosemide administration is 1500 mg. _ _ _Children_ Oral doses for children range from 1 to 3 mg/kg body weight daily up to a maximum total dose of 40 mg/day. _ _ _Elderly_ The dosage recommendations for adults apply, but in the elderly furosemide is eliminated more slowly in general. Dosage should be titrated until the required response is achieved. 4.3 CONTRAINDICATIONS Patients with hypovolaemia or dehydration, anuria or renal failure with anuria not responding to furo 전체 문서 읽기